Cargando…

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current treatment recommendations and guidelines for adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Ward, Ruaa, Zsembery, Celeste, Habra, Mouhammed Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259337/ https://www.ncbi.nlm.nih.gov/pubmed/37435451 http://dx.doi.org/10.1530/EO-22-0050

Ejemplares similares

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
por: Bedrose, Sara, et al.
Publicado: (2020)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

The Immunotherapy Landscape in Adrenocortical Cancer
por: Pegna, Guillaume J., et al.
Publicado: (2021)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

RF19 | PSUN33 Adrenocortical Carcinoma as a Rare Manifestation of Birt-Hogg-Dubé Syndrome
por: Else, Tobias, et al.
Publicado: (2022)

PSAT010 Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma
por: Murvelashvili, Natia, et al.
Publicado: (2022)

Current management options for recurrent adrenocortical carcinoma
por: Glover, Anthony R, et al.
Publicado: (2013)

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

Prognostic Factors for Adrenocortical Carcinoma Outcomes
por: Scollo, Claudia, et al.
Publicado: (2016)

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
por: Stigliano, Antonio, et al.
Publicado: (2012)

FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
por: Brondani, Vania B, et al.
Publicado: (2023)

Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
por: Srougi, Victor, et al.
Publicado: (2017)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Clinical and Histopathological Variables and Prognostic Factors of Adrenocortical Carcinoma
por: Sohail, Sara, et al.
Publicado: (2021)

Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options
por: Hescheler, Daniel Alexander, et al.
Publicado: (2022)

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma
por: Karwacka, Izabela, et al.
Publicado: (2021)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Alternative Splicing Events and Splicing Factors Are Prognostic in Adrenocortical Carcinoma
por: Lv, Jian, et al.
Publicado: (2020)

Laparoscopic Adrenalectomy for Large Adrenocortical Carcinoma
por: Machado, Norman Oneil, et al.
Publicado: (2015)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art
por: Lebastchi, Amir H., et al.
Publicado: (2012)

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Yongquan, et al.
Publicado: (2018)

Retroperitoneal Hemorrhage from Adrenocortical Carcinoma as a Poor Prognostic Factor
por: Kasperlik-Zaluska, Anna A., et al.
Publicado: (2008)

Survival and prognostic factors for adrenocortical carcinoma: a single institution experience
por: Loncar, Zlatibor, et al.
Publicado: (2015)

Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis
por: Zhu, Jiawei, et al.
Publicado: (2020)

Apoptosis regulation in adrenocortical carcinoma
por: Pereira, Sofia S, et al.
Publicado: (2019)

Medical Approaches in Adrenocortical Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2020)

Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
por: Mattila, Kalle E., et al.
Publicado: (2022)

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma
por: Xu, Wen-Hao, et al.
Publicado: (2019)

Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma
por: Liang, Weiwei, et al.
Publicado: (2021)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

The challenge of developmental therapeutics for adrenocortical carcinoma
por: Costa, Ricardo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l13lb1la964u22m7lb8g8u4hqc